NCT07328737招募中不适用
Efficacy and Safety of One vs Three Cycles of Hyperthermic Intraperitoneal Chemotherapy After Cytoreductive Surgery for Pseudomyxoma Peritonei: A Multicenter Randomized Controlled Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 132
- 试验地点
- 1
- 主要终点
- 1-year progression-free survival rate
研究概览
简要总结
The goal of this clinical trial is to compare the efficacy and safety of one versus three sessions of hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery (CRS) for patients with pseudomyxoma peritonei (PMP).
The main questions it aims to answer are:
- Does receiving three HIPEC sessions lead to better Progression-Free Survival (PFS) and Overall Survival (OS) compared to one session?
- What are the differences in postoperative complications (e.g., infection, bowel obstruction, myelosuppression) and organ toxicity (e.g., liver/kidney injury) between the two regimens?
- How do the different treatment schedules impact patients' quality of life?
Researchers will compare the experimental group (3 HIPEC sessions) to the control group (1 HIPEC session) to investigate the efficacy and safety of the additional sessions.
Participants will:
- Be randomly assigned to one of two groups:
- Control Group: Receive only a single intraoperative HIPEC session following CRS.
- Experimental Group: Receive two additional HIPEC sessions after CRS+HIPEC (on post-operative day 2 and day 4) at reduced drug doses.
- Undergo scheduled safety checks for side effects on days 1, 3, 5, 7, and 10 post-HIPEC.
- Attend a follow-up visit at 1 month after CRS+HIPEC and, if eligible, receive 6 cycles of standard postoperative chemotherapy.
- Attend regular long-term follow-up visits for several years, which will include physical examinations, blood tests (for tumor markers), CT scans, and quality-of-life questionnaires (EORTC QLQ-C30 version 3.0).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily consent to participate, sign informed consent, and be willing and able to comply with the study protocol;
- •Age 18-70 years;
- •Undergo CRS+HIPEC with pathological diagnosis of PMP of high grade with signet-ring cells, high grade, or low grade;
- •Karnofsky performance status (KPS) >60;
- •Adequate function of major organs as follows:
- •Hematology: WBC ≥3.5×10^9/L, ANC ≥1.0×10^9/L, LC ≥0.5×10^9/L, PLT ≥80×10^9/L, Hb ≥90 g/L;
- •Hepatic function: AST, ALT, and TBIL ≤2×upper limit of normal (ULN);
- •Renal function: serum creatinine <1.2×ULN;
- •Coagulation: APTT ≤1.5×ULN; INR or PT ≤1.5×ULN;
- •Cardiopulmonary function sufficient to tolerate major surgery and HIPEC;
- •(5) Radiological Peritoneal Cancer Index (PCI) ≥15; (6) No local or systemic antitumor therapy within 1 month prior to CRS+HIPEC; (7) Adverse reactions from prior treatments have resolved before study initiation or, in the investigator's judgment, will not interfere with this study;
排除标准
- •Metastases to lung, brain, bone, or liver;
- •AST, ALT, or TBIL ≥2×ULN;
- •Serum creatinine ≥1.2×ULN;
- •Severe mesenteric contraction;
- •Major organ dysfunction that cannot support the planned procedures;
- •Concomitant hematological disorders or other malignancies;
- •Acute or subacute infectious disease;
- •History of allergy to cisplatin or docetaxel, or marked allergic diathesis or severe allergy history;
- •Psychiatric or psychological disorders preventing cooperation with treatment and efficacy evaluation;
- •Any other condition deemed unsuitable for enrollment by the investigator;
结局指标
主要结局
1-year progression-free survival rate
时间窗: From randomization until 12 months postoperatively.
serious adverse events incidence
时间窗: From randomization until 1 months postoperatively.
次要结局
- progression-free survival(From randomization until 3 years postoperatively.)
- Overall survival(From randomization until 3 years postoperatively.)
研究者
Yan Li
Professor of Oncology and Director of the Department of Peritoneal Oncology
Beijing Tsinghua Chang Gung Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
3 期
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic RhinitisNCT07291284Longbio Pharma546
已完成
1 期
A Phase 1 MAD Study of KINE-101 in Healthy VolunteersNCT07324642Kine Sciences Co., Ltd.24
进行中（未招募）
2 期
Taldefgrobep Alfa in Adults With Overweight and ObesityObesityNCT07281495Biohaven Therapeutics Ltd.150
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
招募中
3 期
A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCANCT07282353Cascade Pharmaceuticals, Inc135